Alere, InDevR Win BARDA Contracts To Develop Rapid Influenza Tests
This article was originally published in The Gray Sheet
Two rapid test manufacturers, Alere and InDevR, win multi-million dollar, multiple-year contracts with HHS’s Biomedical Advanced Research and Development Authority to develop point-of-care diagnostics to swiftly identify pandemic influenza strains from nasal samples.
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.